Cerebral Malaria Therapeutics Market

Posted by Devanand on April 9th, 2021

Cerebral malaria, a severe neuropathological complication, primarily caused by Plasmodium falciparum. The infectious disease has become prevalent in tropical and sub-tropical countries. The cerebral malaria therapeutics market has evolved on the back of increased understanding of pathogenesis of the neurological syndrome. A growing array of biomarkers and tool in recent years have helped underpin the growing revenue potential in the market, giving rise to numerous therapeutic approaches to the healthcare community.

Read Report Overview - https://www.transparencymarketresearch.com/cerebral-malaria-therapeutics-market.html

The high mortality of the disease has lend itself to intense scrutiny by the research community, and has coaxed them to relentlessly make efforts in understanding the pathophysiology of the disease. Specific anti-malarial therapy coupled with adjunctive therapy has expanded the outlook of therapeutics for this life-threatening disease. Adjunctive therapy modulates the host response to infection, and has garnered interest of industry players in the cerebral malaria market.

Global Cerebral Malaria Therapeutics Market: Trends and Opportunities

A large number of candidate therapeutics are present in clinical trials for fighting the incidence of this non-traumatic encephalopathies. The study on the cerebral malaria therapeutics market offers a critical assessment of the major clinical developments shaping the drug pipeline of antimalarial drugs. The various insights take a closer look at policy frameworks prevalent in countries that are high risks of the death from the syndrome, such as in sub-Saharan Africa and South East Asia. These analyses thus offers in-depth insights into the key trends and drivers shaping the potential opportunities in the market. The advent of cutting-edge imaging technologies in malaria-endemic countries has changed the recent course of growth in the cerebral malaria therapeutics market. Nonetheless, they are still to get mainstreamed in the healthcare systems of these countries.

Request Brochure –


In numerous malaria-endemic countries, the application of computed tomography has been associated with large benefits to the patient populations. The growing application will help bolster avenues in cerebral malaria therapeutics market. Advances in neuroimaging techniques have shed light on the pathogenesis of the disease. Advances in in vivo bioluminescent imaging have further widened the scope of new therapeutics.

Malaria causes somewhere between millions of deaths each year, and at least 429,000 deaths annually according to an estimate. Particularly, the mortality of cerebral malaria is 10 – 15% despite intense care and the uptake best antimalarial drugs in patients. This presents an unmet need for drug makers. A better understanding of neurological sequelae by researchers help. In this connection, artemisinin derivatives have attracted the attention of worldwide researchers.


Global Cerebral Malaria Therapeutics Market: Regional Landscape

Key regional segments in the cerebral malaria therapeutics market are North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. Of these, Asia Pacific and the Middle East and Africa are expected to gain momentum in the next few years. The growth is driven by players strengthening the drug pipeline for countries where diseases have high prevalence and mortality rate. On the other hand, parts of North America plays crucial role in the global cerebral malaria therapeutics market. The regional market is expanding on the back of growing body of research on understanding the neurological aspects of tropical disease.

Global Cerebral Malaria Therapeutics Market: Companies Profiled in the Report

The study offers a scrutiny of factors and trends that impact the evolving competitive dynamics of the cerebral malaria therapeutics market. Some of the key players profiled in the report are Cipla, Inc., Sun Pharmaceutical Industries Ltd., Novartis AG, Ajanta Pharma, Astra Zeneca plc., and Sanofi.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Like it? Share it!


About the Author

Joined: April 9th, 2021
Articles Posted: 216

More by this author